Favipiravir – a modern antiviral drug: synthesis and modifications

Yulia A. Titova1*, Olga V. Fedorova1

1 Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, 22 S. Kovalevskaia St., Yekaterinburg 620108, Russia; e-mail: titova@ios.uran.ru

The routes of synthesis are considered, as well as the modifications of the promising modern antiviral drug favipiravir. Literature data from the last 10 years are reported.

Keywords: favipiravir, oseltamivir, pyrazine, ribonucleoside, coronavirus, antiviral activity.

Favipiravir (T-705, 6-fluoro-3-hydroxyprazin-2-carboxamide) is a novel low molecular weight antiviral compound. It has shown activity against many types of RNA viruses (all strains of influenza A, B, C, arenavirus, bunyavirus, flavivirus, alphavirus, norovirus,1 as well as the Zika, Usutu,2 and Ebola3 viruses). The generally good tolerance of human patients to favipiravir and the high barrier to the development of resistant viral strains indicate that this drug holds great promise for clinical use around the world. It should be noted that a representative of the Zhejiang Hisun Pharmaceutical company from China has announced that this company has received marketing authorization from the Chinese government for favipiravir as a possible medication against the coronavirus causing Covid-19.4

**Synthesis of favipiravir**

Favipiravir (1) was first synthesized in 2000 by a route consisting of seven steps. The starting material was 3-amino-6-bromopyrazine-2-carboxylic acid (2). The amination step was catalyzed by a costly (S)-(−)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl ((S)-BINAP), fluorination required using the highly corrosive Olah reagent, while the overall reaction yield was approximately 0.44% (Scheme 1).5

Improved methodologies for the synthesis of favipiravir (1) have been reported in recent years. In particular, a four-step method enabled the synthesis of favipiravir (1) from commercially available 3-hydroxyprazin-2-carboxylic acid (3), which was subjected to esterification and amidation. The nitration of pyrazine ring was followed by reduction of the nitro group in the presence of Raney nickel, allowing to minimize the amount of byproducts. After the replacement of amino group with a fluoride atom, the overall yield of the target product 1 was 8%6 (Scheme 2).

A research group from China proposed a route for the synthesis of favipiravir (1) through a key intermediate – methyl 3-amino-6-bromopyrazine-2-carboxylate (4). According to them, the purity of this compound was
important for successful preparation of 3,6-dichloropyrazine-2-carbonitrile (5). In addition, a one-pot procedure involving substitution of chlorine atom with fluorine, hydrolysis, and aminolysis of nitrile group was demonstrated\(^7\) (Scheme 3).

The preparation of favipiravir (1) from pyrazin-2-amine (6) has been accomplished via regioselective chlorination of pyrazine ring, bromination, palladium-catalyzed cyanation, diazotation, and Sandmeyer chlorination. The subsequent nucleophilic fluorination, nitrile hydrolysis, and replacement of fluorine atom with a hydroxy group provided the target product 1 in 12–18% yield, depending on the reaction conditions for the first step of the synthesis\(^8\) (Scheme 4).

A nontrivial method for the preparation of favipiravir (1) has been proposed, starting from ethyl diethoxyacetate (7) through the fluorinated isoxazolo[4,5-b]pyrazine derivative 8, followed by isoxazole ring cleavage\(^9\) (Scheme 5).

The main directions of modification applied to favipiravir

As shown in 2013, the key limiting step in the antiviral action mechanism of favipiravir (1) is its transformation into the active metabolite – favipiravir ribonucleoside triphosphate.\(^10\) This discovery motivated studies aimed at the preparation of favipiravir derivatives on the basis of various monosaccharides, such as the synthesis of favipiravir ribosides, as well as favipiravir ribonucleoside-5-monophosphate (9) (Scheme 6). The low stability of the obtained ribonucleosides was noted even under mild conditions: the nucleosidic bond was prone to cleavage, as well as the heterocyclic fragment underwent decomposition.\(^11\)

The alkylation of phosphate moiety in favipiravir ribosides has been also described (Scheme 7). The obtained compounds exhibited antiviral activity, comparable to favipiravir.\(^12\)
A similar modification of 6-fluoro-3-hydroxypyrazine-2-carboxamide (1) has been described, involving oxathiolane derivative 10. The cis-isomer of the obtained 2-(hydroxymethyl)oxathiolane-containing favipiravir derivative 11 (Scheme 9) showed activity against the H1N1 influenza virus, while the trans-isomer had activity against HIV.\textsuperscript{14}

The combination of favipiravir (1) and the antiviral drug oseltamivir (12) in one molecule (Scheme 10) produced an advantageous synergic effect. The obtained compound 13 showed improved antiviral activity against the H5N2 influenza virus.\textsuperscript{15}

The attempts to perform alkylation of favipiravir (1) with nitrogen-containing acyclic phosphonates 14 by using the Mitsunobu reaction led to the preparation of N- and O-regioisomers 15 and 16. However, N-isomer 15 was found to be unstable under the conditions used for the removal of protecting groups (Scheme 11). Some of the obtained O-regioisomers 16 selectively inhibited the human enzymes HGPRT and PfHGXPRT. Also, the oxygen-containing acyclic phosphonates employed as alkylating agents led only to the O-alkylation products of favipiravir (1).\textsuperscript{16}
The preparation of favipiravir phosphate 17 has been described (Scheme 12), and this derivative was characterized by improved solubility and pharmacokinetic properties.\(^\text{17}\)

**Scheme 12**

The preparation of favipiravir phosphate 17 has been described (Scheme 12), and this derivative was characterized by improved solubility and pharmacokinetic properties.\(^\text{17}\)

Cyctobutane-containing favipiravir derivatives 18 (Scheme 13) were active against a series of influenza virus strains.\(^\text{18}\)

**Scheme 13**

This work was performed within the scope of a State contract (No. AAAA-A19-119011790134-1).

References

1. (a) Furuta, Y.; Gowen, B. B.; Takahashi, K.; Shiraki, K.; Smee, D. F.; Barmand, D. L. *Antivir. Res.* **2013**, 100, 446. (b) Delang, L.; Abdelnabi, R.; Neyts, J. *Antivir. Res.* **2018**, 153, 85.
2. (a) Pires de Mello, C. P.; Tao, X.; Kim, T. H.; Bulitta, J. B.; Rodriguez, J. L.; Pomeroy, J. J.; Brown, A. N. *Antimicrob. Agents Chemother.* **2018**, 62, 1. (b) Bassi, M. R.; Sempere, R. N.; Meyn, P.; Polacek, C.; Arias, A. *Antimicrob. Agents Chemother.* **2018**, 62, e00380-18. (c) Segura Guerrero, N. A.; Sharma, S.; Neyts, J.; Kaptein, S. J. *F. Antivir. Res.* **2018**, 160, 137.
3. (a) Madelain, V.; Baize, S.; Jacquot, F.; Reynard, S.; Fiset, A.; Barron, S.; Solas, C.; Lacarelle, B.; Carbonnelle, C.; Mentré, F.; Raoul, H.; de Lamballerie, X.; Guedj, J. *Nat. Commun.* **2018**, 9, 1. (b) Smither, S. J.; Eastaugh, L. S.; Stewart, J. A.; Nelson, M.; Lenk, R. P.; Lever, M. S. *Antivir. Res.* **2014**, 104, 153.
4. https://www.rbc.ru/society/16/02/2020/5e496d289a79473f7e35190a
5. Furuta, Y.; Egawa, H. WO Patent 20000/10569.
6. Shi, F.; Li, Z.; Kong, L.; Xie, Y.; Zhang, T.; Xu, W. *Drug Discoveries Ther.* **2014**, 8, 117.
7. Liu, F.-L.; Li, C.-Q.; Xiang, H.-Y.; Feng, S. *Chem. Pap.* **2017**, 71, 2153.
8. Guo, Q.; Xu, M.; Guo, S.; Zhu, F.; Xie, Y.; Shen, J. *Chem. Pap.* **2019**, 73, 1043.
9. Nakamura, K.; Murakami, T.; Naitou, H.; Hanaki, N.; Watanabe, K. US Patent 20150013921.
10. Naesens, L.; Guddat, L. W.; van Kuilenburg, A. B. P.; Meijer, J.; Vande Voorde, J.; Balzarini, J. *Mol. Pharmacol.* **2013**, 84, 615.
11. Huchting, J.; Winkler, M.; Nasser, H.; Meier, C. *ChemMedChem* **2017**, 12, 652.
12. Zhong, B.; Fan, S.; Zhou, L.; Shi, W.; Yao, Y.; He, X.; Jia, H. CN Patent 103833812.
13. Li, S.; Li, X.; Zhong, W.; Zhang, Z.; Wang, L.; Zheng, Z.; Zhou, X.; Zhao, G.; Wang, X. WO Patent 2013139206.
14. Han, M.; Zhao, X.; Wu, X.; Huang, W.; Li, X.; Yu, F. *Med. Chem.* **2018**, 14, 595.
15. Liu, X.; Zhang, T.; Zhan, P.; Zhang, J.; Ju, H. CN Patent 108299316A.
16. Klejch, T.; Pohl, R.; Janeba, Z.; Sun, M.; Keough, D. T.; Guddat, L. W.; Hockova, D. *Tetrahedron* **2018**, 74, 5886.
17. Wu, Y. CN Patent 105884827.
18. Ren, Q.; Luo, H.; Tang, C.; Zhang, J.; Zhang, Y. CN Patent 104447583.